CLBT
$14.69
Cellebrite DI Ltd.
Recent News
Artisan Small Cap Fund Picked Cellebrite (CLBT) Following New Product Cycle Analysis
Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Small Cap Fund”. A copy of the letter can be downloaded here. The Fund seeks to invest in companies that possess franchise characteristics, with strong earnings trajectories, and are trading at a discount to the estimated private market value. Despite strong results […]
What Gives Cellebrite DI Ltd. (CLBT) a Competitive Moat?
Voss Capital, LLC, an investment management company, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Voss Capital’s funds, Voss Value Fund, LP, and the Voss Value Offshore Fund, Ltd returned -2.1% and -2.2%, respectively, to investors net of fees and expenses, in the fourth quarter compared to a […]
Cellebrite DI (CLBT) Valuation Check After Recent 7% Weekly Share Price Rebound
Cellebrite DI: recent performance snapshot Cellebrite DI (NasdaqGS:CLBT) has been on investors’ radar after a strong 7% move over the past week, contrasting with a negative past 3 months total return and weaker year to date and 1 year figures. At a last close of US$15.30, the digital forensics specialist carries a value score of 3, with reported annual revenue of US$475.675m and net income of US$77.813m from its legally sanctioned investigations software suite. See our latest analysis for...
Cellebrite DI Expands Case-to-Closure Platform With AI Tools, Corellium and Drone Forensics Update
Cellebrite DI (NASDAQ:CLBT) is expanding its “Case-to-Closure” platform with a growing set of digital forensics, evidence management, analytics, and AI-driven investigative tools, CFO Dave Barter said during a Morgan Stanley conference discussion. Barter described how the company’s products are used
Does Cellebrite DI (CLBT) Offer Value After Recent Share Price Weakness?
If you are wondering whether Cellebrite DI's share price really lines up with its underlying worth, this article walks through the key valuation angles that matter for you. The stock last closed at US$13.16, with returns of 10.1% decline over 7 days, 17.1% decline over 30 days, 26.2% decline year to date, 31.2% decline over 1 year, 128.1% over 3 years and 26.3% over 5 years, pointing to shifting expectations over different time frames. Recent coverage has focused on Cellebrite DI's role in...